Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck KGaA Follows Pfizer With Archemix Deal For Aptamer-Based Therapeutics

This article was originally published in The Pink Sheet Daily

Executive Summary

German drug maker's new subsidiary, Merck Serono, will oversee development of aptamer-based drugs to treat cancer.

You may also be interested in...



Takeda, Merck KGaA Sign Aptamer Development Deals With Archemix

Archemix has signed separate agreements with Takeda and Merck KGaA to develop therapeutics based on aptamers, the firms announced June 11

Takeda, Merck KGaA Sign Aptamer Development Deals With Archemix

Archemix gets $6 million up-front in Takeda deal; Merck agrees to make $29.8 million equity investment in Cambridge, Mass. company.

Takeda, Merck KGaA Sign Aptamer Development Deals With Archemix

Archemix gets $6 million up-front in Takeda deal; Merck agrees to make $29.8 million equity investment in Cambridge, Mass. company.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS065021

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel